01—Abstract
Summary
Summary of the 8-K filed March 14, 2024. Cited figures are marked; the original filing is the authoritative source.
On March 14, 2024, Omega Healthcare Investors, Inc. filed an automatic shelf registration statement on Form S-3ASR (File No. 333-277916) to replace its prior automatic shelf registration statement (File No. 333-256084, filed May 13, 2021).
The prior registration statement was terminated upon the new one becoming effective on March 14, 2024. This filing is administrative in nature and does not itself disclose financial results or operating performance. In connection with the new registration statement, the company filed two prospectus supplements on the same date.
The first, the DRCSPP Prospectus Supplement, continues the offering of common stock under the company's Dividend Reinvestment and Common Stock Purchase Plan, previously covered by an August 5, 2021 prospectus supplement, and registers an aggregate of 14,152,369 shares of common stock for issuance. The second, the ATM Prospectus Supplement, continues the at-the-market equity offering under its existing sales agreement with multiple sales agents, forward sellers and forward purchasers, previously covered by a May 20, 2021 prospectus supplement. The filing states that it does not constitute an offer to sell or a solicitation of an offer to buy securities.
The filing attaches legal opinions from Shapiro Sher Guinot & Sandler, P.A. and Bryan Cave Leighton Paisner LLP, along with related consents, and includes the cover page interactive data file. It was signed by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary.
02—Key points
Key Highlights
- Filed a new automatic shelf registration statement on Form S-3ASR (File No. 333-277916) on March 14, 2024, replacing the prior shelf registration filed May 13, 2021.
- The prior registration statement (File No. 333-256084) was terminated upon effectiveness of the new registration statement on March 14, 2024.
- DRCSPP Prospectus Supplement continues the Dividend Reinvestment and Common Stock Purchase Plan and registers an aggregate of 14,152,369 shares of common stock ($0.10 par value) for issuance.
- ATM Prospectus Supplement continues the at-the-market equity offering program with multiple sales agents, forward sellers and forward purchasers, covering issuance shares and forward shares.
- The ATM program continues offerings previously covered by a prospectus supplement filed May 20, 2021, and the DRCSPP continues offerings covered by a prospectus supplement filed August 5, 2021.
- Legal opinions and consents from Shapiro Sher Guinot & Sandler, P.A. and Bryan Cave Leighton Paisner LLP are attached as exhibits.
03—Questions
Frequently Asked Questions
What did Omega Healthcare Investors file on March 14, 2024?
The company filed an automatic shelf registration statement on Form S-3ASR (File No. 333-277916) to replace its prior shelf registration statement, along with two prospectus supplements covering its dividend reinvestment plan and at-the-market equity offering.
Does this filing reflect a new equity raise?
The filing states that it does not constitute an offer to sell or a solicitation of an offer to buy any securities. It describes continuing existing offering programs under the new registration statement rather than announcing a specific new sale of securities.
How many shares are registered under the dividend reinvestment plan?
The DRCSPP Prospectus Supplement registers an aggregate of 14,152,369 shares of common stock for issuance under the Dividend Reinvestment and Common Stock Purchase Plan under the new registration statement.
What happened to the prior shelf registration statement?
The prior automatic shelf registration statement (File No. 333-256084, filed May 13, 2021) was terminated upon the effectiveness of the new registration statement on March 14, 2024.
Who signed the filing?
The filing was signed on behalf of Omega Healthcare Investors, Inc. by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary, dated March 14, 2024.
04—Continue